P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study

M Fedyanin,F Moiseenko,M Lyadova,E Vorobeva,O Gladkov,V Petkau,A Fateeva,E Kuzmina,O Novikova,V Chubenko,N Abduloeva,A Kudryavtsev,E Ignatova,R Shakirov,O Pardabekova,L Kindyalova,S Pelikh,S Tjulandin,A Tryakin

doi:10.1016/j.annonc.2021.05.176

P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study

M Fedyanin, F Moiseenko + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2021.05.176

Copy DOI

Journal: Annals of Oncology	Publication Date: Jul 1, 2021
License type: publisher-specific-oa

Affiliation: State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care, Ministry of Health of the Russian Federation, Ural State Medical University, Moscow City Oncology Hospital №62

#Treatment Of Metastatic Colon Cancer #Biosimilar Bevacizumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A biosimilar of bevacizumab was registered in Russia in 2015 based on the results of a randomized trial in patients with NSCLC. We performed a comparison of the efficacy and tolerability of a combination of chemotherapy with the original bevacizumab from Roche and biosimilar bevacizumab from Biocad in patients with metastatic colon cancer in the second line of treatment.

Full Text